Adjuvant Therapy for Early-Stage HER2+ Breast Cancer

With the advent of recent data, there is a focus on incorporating them into the treatment planning of HER2-positive early breast cancer. Adam M. Brufsky, MD, PhD, FACP, leads panel of experts, Kimberly Blackwell, MD; Hope S. Rugo, MD; and Lee Schwartzberg, MD, FACP, on addressing some of the questions surrounding adjuvant treatment of HER2-positive early breast cancer and how they interpret the available data.